NCNA NuCana plc

Nasdaq nucana.com


$ 3.44 $ -0.08 (-2.29 %)    

Friday, 14-Nov-2025 15:28:53 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 3.41
$ 3.32
$ 3.43 x 140
$ 3.52 x 115
$ 3.32 - $ 3.43
$ 2.78 - $ 330.00
48,634
na
2.42M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nucana-announces-chinas-national-intellectual-property-administration-has-granted-a-composition-of-matter-patent-for-nuc-7738-its-novel-anti-cancer-agent

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that the China National Intellectual Property Ad...

 reported-saturday-nucana-highlights-synergy-between-nuc-7738-and-pd-1-inhibitors-in-rcc-organoids-supporting-expansion-of-nutide701-clinical-study

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy an...

 nucana-publishes-nutide303-clinical-and-preclinical-data-on-nuc-3373-in-medrxiv-and-plos-one

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated PatientsLatest Data ...

 nucana-cancels-all-remaining-series-a-warrants-after-raising-required-capital-eliminating-overhang-from-may-2025-offering

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces it has successfully canceled all remaining Serie...

 nucana-announces-1-for-200-ads-ratio-change-effective-august-8-2025

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced plans to change the ratio of its American Deposi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION